The Know AML website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and Know AML cannot guarantee the accuracy of translated content. Know AML and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
When should patients being treated for acute myeloid leukemia get a COVID-19 vaccination booster?
Luis-Esteban Tamariz-Amador
July 1, 2022
During the EHA 2022 Congress, Know AML spoke with Luis-Esteban Tamariz-Amador, University of Navarra, Pamplona, ES. We asked, When should patients being treated for acute myeloid leukemia get a COVID-19 vaccination booster.
Tamariz-Amador begins by highlighting the increased risk of developing severe COVID-19 for patients with hematologic malignancies, and the varying risks among different types, with patients with acute myeloid leukemia being at a particular high risk. Tamariz-Amador also notes that the likelihood of the COVID-19 vaccine inducing seroconversion is also increased for patients with acute myeloid leukemia compared to lymphoproliferative disorders or multiple myeloma. Finally, Tamariz-Amador discusses the number of doses, vaccine type, and when to get a vaccination booster.
To what extent do you agree with the following statements?
Please rate between 1 and 5, with 1 being 'strongly disagree' and 5 being 'strongly agree'.
